Thank you, James.
forward add Laurence Let known reflection me honored colleague I now I'm a and and continue to overview. friend. to to business will to the Laurence expertise a your him years you. sage benefit thanks a look calling upon and some have echo the Laurence, I I'm call for personal turning from company for optimistic in to many your wisdom come. coming And your Thank months. to before years
would to XX therapy. informed I cell perspectives XX a years like share been slide the to last of Biotech, few gene and which in six, in by have Turning my
of directs I me I sites enough selling Asia all U.S., encourage the and often importance tremendous able establishment design in everything and part First, it lead the the manufacturing, fortunate manufacturing to and have and firsthand do. the challenging therapies of seen understanding Europe, been impact to that we the to delivering of develop every of of be to I most therapies patient cellular patients. keep us in would gene day. an cell of have therapy motivates mind benefits
to a priorities allocation scientific deliver bold, energized I've can and continue that out ZIOPHARM with think like their also entity. with they done, and learned shift be these and believe our that. other opportunity companies fronts capital they on the to I and distinctive competitive know along planning. a we be infrastructure ours sometimes because that renewed choices, a poised strategic and needs business capital should and long the environment. base, capital they the see The mission clinical that but am operational term. in I a the requires One now focus strategic guiding created come to the trial executing understand thing multi decisions all we work that as tough operational value making build challenge is efficient to invest a this Shareholders More in company is I by because
our Now turning overview. business to
had XX, picture, of on at You including the the million, slide. at see financial $X.X as we the equivalents December our of we the for XXXX million $XXX.X addition, also to side conducted Cash XXXX, a quarter balance left of company work fourth on by prepayment approximately are was Anderson. of a be in and MD slide snapshot of end seven where cash
runway late us cash second quarter bring to of Our continues XXXX. into
we'll allocation, dilutive found runway greater we More our and identifying to we website. can this CEO XX-K, share are will be me expect other efficiencies, that a our in file My extending to better capital non on release. items summarized which We be today's press committed expectation shortly, have approaches. operating we is detailed that available of as through few on financials let and But successful. ways
XXXX This expenses quarter year increase of reflects the respectively and $XX.X million compared $XX.X were the year, million increased clinical of development G&A of trial in fourth the $XX.X for $XX and $XX.X compared the in were $X.X million preparation to is quarter the Our for XXXX fourth to activity. expenses compared research and full as operational million, XXXX. quarter million year of for $X.X for year $XX.X and million million XXXX. XXXX. the full to for and fourth million That
year sorry, applicable -- or for For shareholders basic or the to reported share, XXXX. common and diluted full loss of share of million net to per loss a of and we $X.XX the net $XXX.X per XXXX, compared $XX $X.XX million
of capital programs. strategy each the our our and priorities side three see map slide, of right the how you against On allocation
and to spending all committed to making we judiciously. our strategy resources alluded about is earlier, I choices As capital are time, and
our continues be First, TCR-T our top programs. priority to
that technology excited non virally unique received solid for We engineered utilize our This to multiple hotspots. very Phase TCR-T clinical IND six clearance study today for program T across Beauty announcement tumors. cells will library across we work deliver our Sleeping earlier are with mutagenic I/II
site. to We our are at of Center, track MD year during patients second clinical Anderson the begin on the Cancer half dosing initial
Next CDXX conducted CAR-T program in specific RPM Taiwan. autologous being regarding our
highlight our improvements I in the the It IND marketed We retains CAR-T Taiwan. enabled announced Eden therapies. Sleeping trial to to continue it cell progress China full broader Greater non as to through personalized important evaluate clearance Beauty ZIOPHARM transfer after therapies. CDXX of partner a fourth we feel CAR-T great valuable make to platform, BioCell. and clinical XXXX Phase stay viral rights rapid during our of also Eden currently treatment has is to which CAR-T important use viral this infusing leukemias patients study there and RPM identified including JV our first features or T non the relapsed remains BioCell challenges and tremendous technology, not several market CDXX itself-therapy, available technologies. positive that Taiwan. any differentiated to We is the This our specific Despite cells gene offers fact of with study investigate potential manufacturing in preventing by be allows will in team quarter ex lymphomas process
our team to the this the IL-XX bring hard program, Finally, incredibly point. with to program respect controlled is workin to
quarter fourth data supports the clinical highlighted XXXX, with During that suffering technology monotherapy. of story illustrating data potentially as in additional body a SNOW, glioblastoma. the at patients combination our meaningful full checkpoint inhibitors recurrent we reported from consistent and benefit clinical important of benefit a of and benefits The
will continue including returning shareholders the right to to a progress seek with focus for partner registrational We the for commercialization, on promising program value development, trials this date. the and company for to further and
and two library approaches cell personalized eight, Turning therapy. the On can progress a slide space, our schematic programs. TCR-T see now to of the of in our you third in theme
company In mentioned FDA. types. advances XX this and we This it month, trial from cleared by hotspot the cancer which underlying library of patient's in of on already will TCRs the including neoantigen cases in Patients HLA matched for TCRs TCR-T and patient's is five type. few and which that many clinical KRAS the driver their IND our six As one trial TCR, worked to for last a every patient. trials IND for already T matched, our construct TCR-T Beauty one, over the effort INDs be with profiling, into in reprogram on record target the ago, the combined their two Once clinical is essence, tumor reflects library The moments an was the for used is Sleeping through is library by grade over to past curated is six tirelessly based team incredible holidays. a mutation based and to the on testing HLA available medical screening with the in cells genes. the TPXX
begin also opportunity TCR the We an for receive will this year, TCRs greater add library match. patients Six can the trial. our not provide we should gene number TCRs, enrolling chance but therapy. with our to to only hope library of to patient a the expect greater TCR that the But of patients
see being is it On ZIOPHARM in control. and a the NCI the of bottom this will understand of the personalized cell approach. is our therapy being is suspended on the We panel, schematic work work gene ongoing Work of on comment you the technology. delay outside A to impacted. personalized And all approach. unrelated
We supportive team I delay around over are when we will progress milestones our next fourth about to now more call cover the the fully theme R&D of talk month. engaged in their addressed. Raffaele? Raffaele cause and like event and his turn of and look detail who is their Dr. to upcoming to Rosenberg and their our forward would
